Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ZEAL

Zealand Pharma A/S (ZEAL) Stock Price, News & Analysis

Zealand Pharma A/S logo

About Zealand Pharma A/S Stock (NASDAQ:ZEAL)

Advanced Chart

Key Stats

Today's Range
$17.59
$17.59
50-Day Range
$16.54
$19.20
52-Week Range
$9.93
$32.94
Volume
N/A
Average Volume
4,965 shs
Market Capitalization
$818.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ZEAL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

ZEAL Stock News Headlines

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Missed the Run So Far? This Is Your Second Chance
According to history, the final stretch of the crypto cycle is here — and this short window is where fortunes are made. Inside The Crypto Code Workshop, two experts reveal how to get positioned early, lock in profits, and access their top altcoin picks before the crowd. All attendees receive $10 in free Bitcoin just for showing up.
See More Headlines

ZEAL Stock Analysis - Frequently Asked Questions

Zealand Pharma A/S (NASDAQ:ZEAL) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($4.61) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($6.31) by $1.70. The firm had revenue of $16.87 million for the quarter, compared to analysts' expectations of $12.21 million. Zealand Pharma A/S had a negative trailing twelve-month return on equity of 111.04% and a negative net margin of 565.44%.

Zealand Pharma A/S (ZEAL) raised $75 million in an IPO on Wednesday, August 9th 2017. The company issued 3,900,000 shares at a price of $19.30 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zealand Pharma A/S investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), Editas Medicine (EDIT), Spectrum Pharmaceuticals (SPPI), AbbVie (ABBV) and CRISPR Therapeutics (CRSP).

Company Calendar

Last Earnings
11/10/2021
Today
7/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ZEAL
CIK
1674988
Employees
355
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($4.09)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$161.99 million
Net Margins
-565.44%
Pretax Margin
-364.34%
Return on Equity
-111.04%
Return on Assets
-56.54%

Debt

Debt-to-Equity Ratio
0.93
Current Ratio
4.79
Quick Ratio
4.78

Sales & Book Value

Annual Sales
$46.54 million
Price / Sales
17.59
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.38 per share
Price / Book
5.20

Miscellaneous

Outstanding Shares
46,538,000
Free Float
45,514,000
Market Cap
$818.60 million
Optionable
Not Optionable
Beta
1.45
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:ZEAL) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners